96 F.4th 327
2d Cir.2024Background
- The case involves a dispute between Regeneron Pharmaceuticals (plaintiff) and Novartis (defendant) regarding alleged antitrust violations and tortious interference with contract related to the market for anti-VEGF medications used to treat certain eye disorders.
- Both companies produce anti-VEGF drugs: Regeneron's EYLEA and Novartis's LUCENTIS, which were sold initially in vials and later also as prefilled syringes (PFSs)—a new, more efficient and safer delivery method preferred by practitioners.
- Regeneron alleged that Novartis, through a secret collaboration with Vetter Pharma, fraudulently procured a patent covering the PFS version and engaged in conduct to unlawfully delay Regeneron's entry to the PFS market.
- The district court dismissed Regeneron's antitrust claims (for failure to plausibly define a PFS-only market and for proposing a market coextensive with a patent) and its tortious interference claim as time-barred.
- On appeal, the Second Circuit analyzed the viability of the PFS-only market definition and Regeneron's right to equitable estoppel regarding the limitations period for the interference claim.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether PFS-only market is a distinct antitrust market | PFSs are not economically interchangeable with vials; demand is inelastic, supported by switching data and industry recognition. | Vials and PFSs contain the same medicine, treat same condition, and are functionally interchangeable, thus a single market. | Court held Regeneron plausibly alleged a distinct PFS-only market based on economic realities, not just functional similarity. |
| Whether an antitrust market can be coextensive with a patent | Market can be defined by economic substitutes even if coextensive with a patent, per standard antitrust principles. | A market cannot be coextensive with a patent except in extraordinary circumstances; otherwise all patents become monopolies. | Court rejected heightened standard; market definition linked to economic analysis, not patent boundaries. |
| Whether the Section 2 (Walker Process) claim was properly dismissed | Fraudulently obtained patent plus exclusionary conduct meets required elements; allegations sufficient. | Regeneron did not meet the requirement because the market definition failed and the patent was not unlawfully procured. | Court held Regeneron's allegations were adequate to proceed on Walker Process grounds. |
| Whether tortious interference claim was time-barred or equitably estopped | Regeneron could not discover interference due to defendants' concealment; claim brought when information surfaced. | Any alleged concealment was broadly directed at the public/USPTO, not specifically at Regeneron; claim untimely. | Court found Regeneron plausibly alleged equitable estoppel preventing limitations defense at motion to dismiss stage. |
Key Cases Cited
- United States v. E.I. du Pont de Nemours & Co., 351 U.S. 377 (1956) (establishes product market analysis via reasonable interchangeability and cross-elasticity of demand)
- Brown Shoe Co. v. United States, 370 U.S. 294 (1962) (sets out practical indicia for determining antitrust product markets)
- Walker Process Equip., Inc. v. Food Mach. & Chem. Corp., 382 U.S. 172 (1965) (antitrust claim may be predicated on enforcement of fraudulently obtained patents)
- Eastman Kodak Co. v. Image Tech. Servs., Inc., 504 U.S. 451 (1992) (market definition is a fact-intensive inquiry based on commercial realities)
- Illinois Tool Works Inc. v. Indep. Ink, Inc., 547 U.S. 28 (2006) (a patent does not necessarily confer market power for antitrust purposes)
- Geneva Pharms. Tech. Corp. v. Barr Labs., Inc., 386 F.3d 485 (2d Cir. 2004) (market definition in pharmaceutical cases may distinguish between functionally similar but economically distinct products)